Writing therapy eases breast cancer drug side effects, study finds
NCT ID NCT04651452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a simple writing exercise about personal values could reduce physical symptoms and stress, and improve medication adherence in 250 breast cancer patients taking aromatase inhibitors. Participants wrote one essay per month for six months, either about their core values or a neutral topic. The study measured symptoms, stress, and medication use with electronic pill bottles.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Value affirmation writing tasks
- What this could lead to
- If it works, this could offer a simple, low-cost way to help breast cancer patients manage side effects and stick with their medication.
- What could go wrong
- This is a completed behavioral study, not a drug trial. The benefits may be small or not last long, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
250 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Breast cancer diagnosis * Prescribed an aromatase inhibitor within four weeks of enrollment or anticipates being prescribed one in the future * Intention to take the prescribed aromatase inhibitor * Fluency in English * Own a smartphone that can support downloaded apps Exclusion Criteria for fMRI component only: * Have implanted metal * Have an implanted electronic medical device * Have an IUD that contains metal * Are currently pregnant * Have a history of claustrophobia * Weigh more than 300 pounds
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Carnegie Mellon University
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?